Effect of Intranasal Rosiglitazone on Airway Smooth Muscle Thickening in a Murine Model of Chronic Asthma
의약학 > 내과학
이진국 , 박찬권 , 강지영 , 이숙영 , 권순석 , 김영균 , 김관형 , 문화식 , 송정섭 , 윤형규
대한결핵 및 호흡기학회
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 189(총1페이지)
0y909885.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Background: Peroxisome proliferator-activated receptors were reported to regulate inflammatory responses in many cells. In this study we examined the effect of intranasal rosiglitazone on airway smooth muscle thickening in chronic asthma model. Method: We developed a mouse model of airway remodeling including smooth muscle thickening in which ovalbumin (OVA)-sensitised mice were repeatedly exposed to intranasal OVA administration twice a week for 3 months. Mice were treated intranasally with rosiglitazone during OVA challenge. Result: Mice chronically exposed to OVA developed sustained eosinophilic airway inflammation and features of airway remodeling. Administration of rosiglitazone intranasally significantly inhibited the development of eosinophilic inflammation and airway smooth muscle remodeling in mice chronically exposed to OVA. The expression of TLR-4 and NF-kB were increased in OVA group and decreased in rosiglitazone group. Treatment of GW9660 (rosiglitazone antagonist) decreased expression of TLR-4 and NF-kB. The level of PGE2 was elevated in OVA group and decreased in rosiglitazone group. Treatment of GW9660 decreased the level of PGE2. Conclusion: These results suggest that intranasal administration of rosiglitazone can prevent not only airway inflammation, but also airway remodeling associated with chronic allergen challenge. This beneficial effect is mediated by inhibition of TLR-4, NF-kB, and PGE2 pathways.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.